A dopamine D1-like receptor-specific agonist improves the survival of septic mice

Koichi Tanaka,Mohammed E Choudhury,Satoshi Kikuchi,Ikuko Takeda,Kensuke Umakoshi,Noriyuki Miyaue,Kanta Mikami,Ayane Takenaga,Harumichi Yagi,Rintaro Shinabe,Hironori Matsumoto,Hajime Yano,Masahiro Nagai,Jun Takeba,Junya Tanaka

DOI: https://doi.org/10.1016/j.isci.2024.109587

IF: 5.8

2024-03-27

iScience

Abstract:In this study, a murine sepsis model was developed using the cecum ligation and puncture (CLP) technique. The expression of the proinflammatory cytokines tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) in the brain increased 6 h after CLP but decreased 24 h later when elevated endogenous dopamine levels in the brain were sustained. Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride reduced dopamine levels in the striatum and increased mortality in septic mice. Dopamine D1-like receptors were significantly expressed in the brain, but not in the lungs. Intraperitoneally administered SKF-81297 (SKF), a blood-brain barrier-permeable D1-like receptor agonist, prevented CLP-induced death of septic mice with ameliorated acute lung injury and cognitive dysfunction and suppressed TNF-α and IL-1β expression. The D1-like receptor antagonist SCH-23390 abolished the anti-inflammatory effects of SKF. These data suggest that D1-like receptor-mediated signals in the brain prevent CLP-induced inflammation in both the brain and the periphery.